Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial single-ascending dose of SAGE-324 for essential tremor

Trial Profile

A phase I trial single-ascending dose of SAGE-324 for essential tremor

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs SAGE-324 (Primary)
  • Indications Epilepsy; Essential tremor; Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jan 2019 According to a Sage Therapeutics media release, the company recently completed this study.
    • 07 Jan 2019 Status changed from planning to completed, according to a Sage Therapeutics media release
    • 07 Aug 2018 According to a Sage Therapeutics media release, top-line results from the study are expected in 4Q 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top